Rockville, Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system. The ACTT-3 trial assessed the efficacy and safety of interferon beta-1a plus remdesivir compared to remdesivir
More
ROCKVILLE, Md., Sept. 28, 2022 – Emmes, a global, full-service Clinical Research Organization (CRO) dedicated
ROCKVILLE, Md., Sept. 28, 2022 – Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and
MoreRockville, Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19
More
